Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C

Cancer Research

Volumn 56, Issue 15, 1996, Pages 3495-3498

  Xia, Hong ^a   Pinto, Tina ^a   Hu, Xun ^a   Benson, Patrick J ^a   Zaren, Howard A ^a   Gupta, Vicram ^a   Singh, Shivendra V ^a  

^a MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 N [2 (4 NITROPHENYLDITHIO)ETHYL]MITOMYCIN C; GLUTATHIONE; MITOMYCIN C DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; BUTHIONINE SULFOXIMINE; CYSTEINE; ENZYME INHIBITORS; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; METHIONINE SULFOXIMINE; MITOMYCIN; MITOMYCINS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0029973856     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Crooke, S. T., and Bradner, W. T. Mitomycin C: a review. Cancer Treat. Rev., 3: 121-139, 1976.
2. Doll, D. C., Weiss, R. B., and Issell, B. F., Mitomycin: ten years after approval for marketing J. Clin. Oncol., 3: 276-286, 1985.
3. Doyle, T. W., and Vyas, D. M. Second generation analogs of etoposide and mitomycin C. Cancer Treat. Rev., 17: 127-131, 1990.
4. Bradner, W. T., Rose, W. C., Schurig, J. E., and Florczyk, A. P. Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio)ethyl] mitomycin C (BMY-25067) Invest. New Drugs, 8: S1-S7, 1990.
5. Dusre, L., Rajagopalan, S., Eliot, H. M., Covey, J. M., and Sinha, B. K. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues. Cancer Res., 50: 648-652, 1990.
6. Xu, B. H., and Singh, S. V. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res., 52: 6666-6670, 1992.
7. Rockwell, S., Kemple, B., and Kelley, M. Cytotoxicity of BMS-181174: effects of hypoxia, dicumarol, and repair deficits. Biochem. Pharmacol., 50: 1239-1243, 1995.
8. Xu, B. H., Gupta, V., and Singh, S. V. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. Br. J. Cancer, 69: 242-246, 1994.
9. Rockwell, S., Sartorelli, A. C., Tomasz, M., and Kennedy, K. A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev., 12: 165-176, 1993.
10. Ross, D., Siegel, D., Beall, H., Prakash, A. S., Mulcahy, R. T., and Gibson, N. W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C Cancer Metastasis Rev., 12: 83-101, 1993.
11. Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L., and Nakanishi, K. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA Science (Washington DC), 235: 1204-1208, 1987.
12. Pan, S. S., Andrews, P. A., Glover, C. J., and Bachur, N. R. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259: 959-966, 1984.
13. Siegel, D., Beall, H., Senekowitsch, C., Kasai, M., Arai, H., Gibson, N. W., and Ross. D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry, 31: 7879-7885, 1992.
14. 5 reductase. Cancer Res., 53: 4907-4912, 1993.
15. Gustafson, D. L., and Pritsos, C. A. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions Cancer Res., 53: 5470-5474, 1993.
16. Willson, J. K. V., Long, B. H., Chakrabarty, S., Brattam, D. E., and Brattain, M. G. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells Cancer Res., 45: 5281-5286, 1985.
17. Hoban, P. R., Walton, M. I., Robson, C. N., Godden, J., Stratford, I. J., Workman, P., Harris, A. L., and Hickson, I. D. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res., 50: 4692-4697, 1990.
18. Pan, S-S., Akman, S. A., Forrest, G. L., Hipsher, C., and Johnson, R. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother. Pharmacol., 31: 23-31, 1992.
19. Xu, B. H., Gupta, V., and Singh, S. V. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C Int. J. Cancer, 58: 686-692, 1994.
20. He, Q-Y., Maruenda, H., and Tomasz, M. Novel bioreductive activation mechanism of mitomycin C derivatives bearing a disulfide substituent in their quinone J. Am. Chem. Soc., 116: 9349-9350, 1994.
21. Beutler, E. Reduced glutathione In: E. Beutler (ed.), Red Cell Metabolism: A Manual of Biochemical Methods, pp. 131-132. New York: Grune & Stratton, 1984.
22. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
23. Verweij, J., Planting, A., van der Burg, M., Stoter, G., de Boer-Dennert, M., Dewji, R., Santabarbara, P., Kolkers, H., and Schellens, J. Phase I study on 4-weekly 6 h infusion of BMY 25067 in patients (pts) with solid tumors. Eur. J. Cancer, 29 (Suppl 6): S119, 1993.
24. Talbot, D. C., Green, J. A., Mitchell, K., Smith, K., Ganesan, T. G., Carmichael, J., Harns, A. L., Dewji, R., and Santabarbara, P. Phase I study of the mitomycin C analogue BMY 25067. Br. J. Cancer, 69 (Suppl. 21): 48: 1994.
25. Ozols, R. F., Hamilton, T. C., Masuda, H., and Young, R. C. Manipulation of cellular thiols to influence drug resistance. In: K. D. Tew and P. V. Woolley (eds.), Mechanisms of Drug Resistance in Neoplastic Cells, Bristol Myers Symposium No 9, pp. 289-305. New York: Academic Press, Inc., 1988.
26. Mitchell, J. B., and Russo, A. The role of glutathione in radiation and drug induced cytotoxicity. Br. J. Cancer, 55: 96-104, 1987.
27. Singh, S. V., Xu, B. H., Maurya, A. K., and Mian, A. M. Modulation of mitomycin C resistance by glutathione transferase inhibitor ethacrynic acid Biochim. Biophys. Acta. 1137: 257-263, 1992.
28. Perry, R. R., Greaves, B. R., Rasberry, U., and Barranco, S. C. Effect of treatment duration and glutathione depletion on mitomycin C cytotoxicity in vitro Cancer Res., 52: 4608-4612, 1992.
29. Sharma, M., and Tomasz, M. Conjugation of glutathione and other thiols with bioreductively activated mitomycin C. Effect of thiols on the reductive activation rate Chem. Res. Toxicol., 7: 390-400, 1994.
30. Nair, S., Singh, S. V., Samy, T. S. A., and Krishan, A. Anthracycline resistance in murine leukemic P388 cells: role of drug efflux and glutathione related enzymes Biochem. Pharmacol., 39: 723-728, 1990.
31. Lee, J-H., Naito, M., and Tsuruo, T. Nonenzymatic reductive activation of 7-N-{{2-{[2-(γ-L-glutamylamino)ethyl]dithio}ethyl}} mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res., 54: 2398-2403, 1994.